ENTITY
Jacobio Pharmaceuticals

Jacobio Pharmaceuticals (1167 HK)

83
Analysis
Health Care • China
Jacobio Pharmaceuticals is a clinical-stage pharmaceutical company dedicated to the in-house discovery and development of innovative oncology therapies, focusing on "undruggable" targets in key oncogenic pathways. They leverage their Induced Allosteric Molecule Discovery Platform and iADC Platform to develop novel drugs, including clinical-stage candidates like Glecirasib (KRAS G12C inhibitor) and Sitneprotafib (SHP2 inhibitor) for various solid tumors. The company was founded in 2015 and is headquartered in Beijing, China.
more
bullish•Alibaba Health
•18 Dec 2020 20:56

China Healthcare: Macro Themes

This Insight summarizes the takeaways from a recent China healthcare industry conference.Ā  There is much talk of pressures on the industry, but...

Share
•18 Dec 2020 15:45

Jacobio (åŠ ē§‘ę€čÆäøš)Ā  IPO Trading: Not for the Impatient

The strong cornerstone list helps with the sentiment. However, as the deal is fairly valued, we think there will be little valuation upside based...

Logo
636 Views
Share
bullish•JD Health
•13 Dec 2020 09:59

ECM Weekly (13 December 2020) - Vesync, Sino-Ocean, Jacobio, Netjoy, Sea, Xpeng, NIO, and More!

Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs.

Share
•10 Dec 2020 17:24

Jacobio (åŠ ē§‘ę€čÆäøš)Ā  IPO: Faith on Founder

We provide a valuation for its SHP products and we think the deal is fairly valued at the low end even considering the founder's background. We...

Logo
556 Views
Share
•10 Dec 2020 08:24

Jacobio: Management Solves for Valuation

We think that the offer terms for Jacobio's IPO are fair, but buyers need to take a long view given the small deal size and shares' limited liquidity.

Share
x